Medicare opens fast lane for pediatric device makers to set their own prices

What it does

This bill amends Medicare's physician fee schedule to allow manufacturers of pediatric medical devices to request that the federal government establish payment rates for their products. When a manufacturer submits a request, the Secretary of Health and Human Services must create a reimbursement value for that device through the annual rulemaking process, using available pricing and claims data. The bill applies only to devices already approved by the FDA, already covered by Medicare, and either used mainly on children or specifically designed for pediatric use.

Why we flagged it

The bill's core function is to create a streamlined process for pediatric medical device manufacturers to obtain Medicare payment rates. It is neither a blanket deregulation nor a broad public-health mandate, but rather a procedural mechanism that benefits a specific industry segment while nominally serving pediatric patients.

What the text implies

• Manufacturers control the timing and initiation of rate-setting; the Secretary has no discretion to decline a request or prioritize devices by clinical need, only to follow the statutory timeline.
• The bill does not require comparative-effectiveness data or cost-benefit analysis before establishing payment rates, relying instead on manufacturer-supplied information and existing pricing data.
• Once a rate is established, the bill contains no sunset, review, or adjustment mechanism; rates persist unless separately modified through future rulemaking.
• The definition of 'qualifying pediatric technology' is broad (any FDA-approved device used 'predominantly' on children or 'specifically designed' for pediatric use) and may capture devices with limited pediatric-specific evidence.
• Medicare's obligation to pay for newly-rated devices is not conditioned on clinical evidence, outcomes data, or demonstration of improved pediatric health outcomes.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Pediatric patients and physicians gain access to newly-reimbursed medical technologies that may improve care, but the bill creates a manufacturer-initiated process that could expand Medicare spending without explicit cost controls or comparative-effectiveness review, potentially raising program costs and premiums for all beneficiaries.

Who stands to gain

• pediatric medical device manufacturers
• device makers with FDA-approved products awaiting Medicare reimbursement

Named in the bill

Secretary of Health and Human Services, Medicare (Title XVIII, Social Security Act), FDA (Federal Food, Drug, and Cosmetic Act), pediatric medical device manufacturers, physician fee schedule

Where it stands

1 cosponsor: 1 Republicans.

• Jan 24, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 24, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.